This study investigated the expression and clinical significance of DOCK4 in ccRCC, hypothesizing that DOCK4 could serve as a prognostic biomarker and correlate with the tumor immune microenvironment (TIME) and immunotherapy response.<h4>Methods</h4>We comprehensively analyzed data on DOCK4 expression levels and prognostic outcomes in ccRCC patients derived from tissue microarray (75 pairs) and the dataset (532 cases). This evidence concerns the gene DOCK4 and neoplasm.